Britain has become the first country in Europe to approve orforglipron, the oral weight loss and diabetes treatment developed by US company...

Britain's regulator approved Eli Lilly's Foundayo pill for weight and diabetes. This treatment is not yet available through the NHS in the ...

Indian pharmaceutical firms experienced a challenging June quarter, marked by declining US business profits. Dr Reddy's and Cipla saw signi...

Novo Nordisk is seeking a court injunction to stop Eli Lilly's drug advertisements. The Danish company claims Lilly's ads mislead consumers...

Cipla is focusing on its tirzepatide brand Yurpeak in India's obesity market. Yurpeak has become the second largest GLP-1 product since its...

Novo Nordisk has sued Eli Lilly in a U.S. court. The Danish company accuses Lilly of false advertising for its weight-loss medicines. Novo ...

India's drug regulator approved Novo Nordisk's Wegovy for MASH treatment. This drug targets a serious progressive form of fatty liver disea...

Novo Nordisk's weight-loss drugs are regaining market share from Indian generics. Innovator brands show steady month-on-month sales growth,...

Eli Lilly's diabetes drug Mounjaro will be added to China's state health insurance from January 1, making it more accessible to the country...

Eli Lilly stock today: Eli Lilly achieved a historic milestone, briefly touching a $1 trillion market cap. This success is driven by strong...

Eli Lilly and Cipla have joined forces. Cipla will now market Lilly's popular weight-loss drug in India. The medication will be sold under ...

Lilly's Mounjaro has rapidly become the second-highest selling drug in India's pharmaceutical market, achieving ₹233 crore in sales within ...

Lilly stock latest news: Eli Lilly's Q2 earnings soared, fueled by Mounjaro and Zepbound's impressive sales, leading to raised full-year gu...

Eli Lilly's Mounjaro demonstrates significant cardiovascular benefits for Type 2 diabetes patients with heart disease, reducing mortality a...

Eli Lilly is exploring partnerships with Indian pharma firms to market its anti-diabetes and weight loss drug Mounjaro, recently launched i...

Eli Lilly will launch Mounjaro in India in 2025. The drug treats type 2 diabetes and obesity. Lilly received marketing authorization in Jul...

SVB Securities believes that the new diabetes drug by Eli Lilly might be able to address patients' obesity and might lead to more significa...